ライフサイエンスコーパス: ANCA

1 ANCA activate primed neutrophils (and monocytes) by bind

2 ANCA activates neutrophils and activated neutrophils dam

3 ANCA negativity was associated with a decreased proporti

4 ANCA negativity was associated with an increased proport

5 ANCA rises correlated with relapses in patients who pres

6 ANCA specificity independently predicts relapse among pa

7 ANCA specificity was predictive of relapse, with PR3 ANC

8 ANCA was investigated in matched sputum and blood sample

9 ANCA-activated neutrophils activate the alternative comp

10 ANCA-activated neutrophils not only induce injury but lo

11 ANCA-activated phagocytes cause vasculitis and necrotizi

12 ANCA-associated vasculitides are characterized by inflam

13 ANCA-associated vasculitis (AAV) is a highly inflammator

14 ANCA-associated vasculitis can be induced in various for

15 ANCA-associated vasculitis features necrotizing crescent

16 ANCA-associated vasculitis is an autoimmune condition ch

17 ANCA-associated vasculitis is the most frequent cause of

18 ANCA-induced phagocyte NADPH oxidase (Phox) may contribu

19 ANCA-induced superoxide and IL-1beta generation were inv

20 ANCA-stimulated neutrophils released NGAL.

21 ANCAs activate neutrophils inducing their respiratory bu

22 ANCAs directed to proteinase 3 and myeloperoxidase (MPO)

23 an increase in ANCA levels, except for the 1 ANCA-negative patient.

24 -SD) follow-up of 49+/-33 months and 18+/-14 ANCA measurements, 89 ANCA rises and 74 relapses were re

25 Anti-proteinase 3 ANCA was associated with HLA-DP and the genes encoding a

26 ry support for the concept that proteinase 3 ANCA-associated vasculitis and myeloperoxidase ANCA-asso

27 a central pathogenic feature of proteinase 3 ANCA-associated vasculitis.

28 ated from patients and chimeric proteinase 3-ANCA induced the release of neutrophil microparticles fr

29 e with myeloperoxidase-ANCA and proteinase 3-ANCA.

30 -33 months and 18+/-14 ANCA measurements, 89 ANCA rises and 74 relapses were recorded.

31 Antineutrophil cytoplasmic Abs (ANCAs) specific for myeloperoxidase (MPO) play a role in

32 elial growth factor, in patients with active ANCA-associated vasculitis compared with patients during

33 Mice and patients with active ANCA-associated vasculitis demonstrated strongly increas

34 ltured neutrophils from patients with active ANCA-associated vasculitis, indicating that increased tr

35 ipheral granulocytes of patients with active ANCA-associated vasculitis.

36 -MPO antibodies, increase sFlt1 during acute ANCA-associated vasculitis, leading to an antiangiogenic

37 Serum from patients with acute ANCA-associated vasculitis disrupted blood flow in the c

38 al models of anti-MPO GN suggest that, after ANCA-induced neutrophil localization, deposited MPO with

39 or EGPA, by the presence or absence of ANCA (ANCA(+) or ANCA(-), respectively).

40 HR 1.89 [95% CI 1.33-2.69], P = 0.0004), and ANCA specificity had the best predictive model fit (mode

41 ationship between anti-LAMP-2 antibodies and ANCA glomerulonephritis.

42 F-alpha, beta2-integrin engagement, C5a, and ANCA by the FcgammaRII receptor.

43 atures necrotizing crescentic GN (NCGN), and ANCA-activated neutrophils contribute to NCGN.

44 uch as IgA nephropathy, lupus nephritis, and ANCA GN; and additional features as detailed herein.

45 t had antineutrophil cytoplasmic antibodies (ANCA) against proteinase 3 (PR3).

46 Antineutrophil cytoplasmic antibodies (ANCA) are positive in ~40% of the cases and more often i

47 Antineutrophil cytoplasmic antibodies (ANCA) are present in many patients, vary in level over t

48 dhood antineutrophil cytoplasmic antibodies (ANCA) associated vasculitides and to identify the import

49 have anti-neutrophil cytoplasmic antibodies (ANCA) specific for myeloperoxidase (MPO).

50 is an antineutrophil cytoplasmic antibodies (ANCA)-associated necrotizing granulomatous vasculitis th

51 genic antineutrophil cytoplasmic antibodies (ANCAs) can result in systemic small vessel vasculitis.

52 e of anti-neutrophil cytoplasmic antibodies (ANCAs) directed against proteinase 3 (PR3).

53 ce of antineutrophil cytoplasmic antibodies (ANCAs) in the phenotypic expression of Churg-Strauss syn

54 hich anti-neutrophil cytoplasmic antibodies (ANCAs) may contribute to the pathogenesis of ANCA-associ

55 Antineutrophil cytoplasmic antibodies (ANCAs) target proteins normally retained within neutroph

56 pical antineutrophil cytoplasmic antibodies (ANCAs) was performed separately using commercially avail

57 ed by antineutrophil cytoplasmic antibodies (ANCAs), but most patients with neuropathy lack ANCAs.

58 serum antineutrophil cytoplasmic antibodies (ANCAs).

59 d in the anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV).

60 ents with antineutrophil cytoplasm antibody (ANCA)-associated vasculitides.

61 with antineutrophil cytoplasmatic antibody (ANCA)-associated glomerulonephritis.

62 ecause anti-neutrophil cytoplasmic antibody (ANCA) and anti-PR3 antibody screening can be negative at

63 xpress anti-neutrophil cytoplasmic antibody (ANCA) antigens, and activation of these cells by ANCA is

64 c and antineutrophilic cytoplasmic antibody (ANCA) testing.

65 del of anti-neutrophil cytoplasmic antibody (ANCA) vasculitis.

66 sis of anti-neutrophil cytoplasmic antibody (ANCA)-associated necrotizing crescentic GN (NCGN) is inc

67 The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a group of diso

68 Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) constitutes life-threa

69 Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a common cause of r

70 causes anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), with rapidly progress

71 s with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis and myasthenia gravis were r

72 Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis exhibits endothelial damage,

73 Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a severe condition encomp

74 -2) in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is controversial because of

75 tening) antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is unknown.

76 free in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, and a pair of urinary prote

77 tosus, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, Crohn's disease, Behcet's d

78 However, 10%-15% of patients are ANCA negative and the cause of their injury is unknown.

79 mimicking a small vessel vasculitis such as ANCA-associated GN, are a very rare manifestation of den

80 -neutrophil cytoplasmic antibody-associated (ANCA-associated) small vessel necrotizing vasculitis is

81 t antineutrophil cytoplasmic autoantibodies (ANCA) are pathogenic.

82 f antineutrophil cytoplasmic autoantibodies (ANCA) in addition to the more commonly known targets pro

83 r antineutrophil cytoplasmic autoantibodies (ANCA).

84 Anti-neutrophil cytoplasmic autoantibodies (ANCAs) are directed against lysosomal components of neut

85 Anti-neutrophil cytoplasmic autoantibody (ANCA) disease rarely occurs in African Americans and ris

86 Antineutrophil cytoplasmic autoantibody (ANCA) vasculitis is a systemic autoimmune disease result

87 asthma and sinusitis, distinguishing between ANCA-negative CSS and PDGFR-negative HES is difficult be

88 ry, we identified a mechanistic link between ANCA-induced neutrophil activation, necroptosis, NETs, t

89 ught to investigate the relationship between ANCA status and the clinical expression of CSS in a case

90 fibrosis, noncystic fibrosis bronchiectasis, ANCA-associated vasculitis and bronchiectasis.

91 e NF-kappaB in primed human neutrophils, but ANCA-stimulated primed neutrophils activated NF-kappaB i

92 By ANCA specificity, categories of GPA, MPA, and kidney-lim

93 ) antigens, and activation of these cells by ANCA is central to ANCA-associated vasculitis and necrot

94 anulomatous inflammation may be initiated by ANCA-induced activation of extravascular neutrophils, ca

95 trials, we advocate classifying patients by ANCA serotype as opposed to the traditional disease type

96 genic human MPO B cell epitope recognized by ANCA in patients with acute vasculitis and the nephritog

97 Stratification by ANCA reveals that EGPA comprises two genetically and cli

98 were evident when analysis was stratified by ANCA type, AAV diagnosis (granulomatosis with polyangiit

99 ts and strongly positive cytoplasmic ANCA (c-ANCA).

100 culocutaneous biopsy results, the positive c-ANCA, and the clinical manifestation, i.e., heart and oc

101 dult-derived treatment regimens in childhood ANCA-associated vasculitides.

102 ding of the clinical phenotypes of childhood ANCA-associated vasculitides and improved our ability to

103 The most common ANCA target antigens are myeloperoxidase (MPO) and prote

104 eta-galactosidase or neuraminidase converted ANCA assay results from negative to positive.

105 reactants and strongly positive cytoplasmic ANCA (c-ANCA).

106 ic cytokine in patients with newly diagnosed ANCA-associated crescentic GN.

107 on of motor and sensory disturbance in EGPA (ANCA related.com).

108 8(+) T cells mediate disease in experimental ANCA-associated vasculitis.

109 linical manifestations, histologic findings, ANCA staining patterns, and the presence of antibodies t

110 Rituximab is effective for ANCA-associated and cryoglobulinemic vasculitis with neu

111 is of patients enrolled in the Rituximab for ANCA-Associated Vasculitis (RAVE) Trial who had renal in

112 histopathological classification system for ANCA-associated vasculitis was recently published, but w

113 rocesses may provide therapeutic targets for ANCA-mediated diseases in humans.

114 ardiolipin, and tested strongly positive for ANCAs in a perinuclear pattern by immunofluorescence.

115 NCA-positive patients, these antibodies from ANCA-negative patients failed to bind the more complexly

116 , in contrast to anti-LAMP-2 antibodies from ANCA-positive patients, these antibodies from ANCA-negat

117 ver, immunoprecipitated immunoglobulins from ANCA(+) sputum allowed extensive extracellular trap form

118 NETs from ANCA-stimulated neutrophils caused endothelial cell (EC)

119 d, presumably neutrophil, NGAL protects from ANCA-induced NCGN by downregulating T(H)17 immunity.

120 2 (lymphocyte recruitment) in the sputa from ANCA(+) patients (P < 0.01).

121 ls were higher in patients who suffered from ANCA-associated renal relapses compared with those in pa

122 tokine-producing anti-MPO T cells and higher ANCA titers than control mice.

123 ce also led to more anti-MPO T cells, higher ANCA titers, and more severe GN after immunization with

124 FcR genotypes, IgA ANCA, and IgG ANCA are potential prognostic and therapeu

125 cR genetics and previously unappreciated IgA ANCA affect clinical presentation.

126 FcR genotypes, IgA ANCA, and IgG ANCA are potential prognostic and therapeutic targets fo

127 fluorescence assays to determine IgA and IgG ANCA positivity, and used Illumina, TaqMan, or Pyroseque

128 When stimulated with IgA and IgG ANCA together, IgG ANCA induced neutrophil activation wa

129 imulated with IgA and IgG ANCA together, IgG ANCA induced neutrophil activation was reduced (P = 0.00

130 e-associated membrane protein-2 (hLAMP-2) in ANCA-associated piFNGN, and have now investigated whethe

131 hodology led to the discovery of MPO-ANCA in ANCA-negative disease that reacted against a sole linear

132 idase (MPO) is a well defined autoantigen in ANCA-associated vasculitis.

133 ibitor of metalloproteinase-1, and CXCL13 in ANCA-associated vasculitis.

134 rial of Rituximab versus Cyclophosphamide in ANCA-Associated Vasculitis trial.

135 production, and neutrophil degranulation in ANCA-stimulated neutrophils in the absence and presence

136 NETs have been consistently detected in ANCA-associated small-vessel vasculitis, and this associ

137 y sought to determine whether differences in ANCA epitope specificity explain why, in some cases, con

138 ibodies and their relationship to disease in ANCA glomerulonephritis are not well described.

139 Management of eye disease in ANCA-associated vasculitis includes local anti-inflammat

140 Given roles for FcRs in ANCA-mediated neutrophil activation and IgA antibodies i

141 m the development of focal necrotizing GN in ANCA-associated vasculitis.

142 re accompanied or preceded by an increase in ANCA levels, except for the 1 ANCA-negative patient.

143 pecificities different from those present in ANCA disease.

144 er for disease activity and renal relapse in ANCA-associated crescentic GN.

145 o cyclophosphamide for inducing remission in ANCA-associated vasculitis.

146 Participants in the Rituximab in ANCA-Associated Vasculitis (RAVE) trial were excluded fr

147 Whether NGAL plays a mechanistic role in ANCA-associated vasculitis is unknown.

148 omerular myeloperoxidase deposition, seen in ANCA-associated vasculitis, may enhance crescentic GN th

149 ntigen gene expression and disease status in ANCA-associated vasculitis, we measured gene-specific DN

150 hat CD8(+) cells are a therapeutic target in ANCA-associated vasculitis, and suggest that a molecular

151 now investigated whether the same is true in ANCA-negative patients.

152 CSS with sufficient documentation, including ANCA status.

153 tion and diagnostic systems that incorporate ANCA specificity, such as PR3 ANCA-positive MPA and MPO

154 with and activated by NET components induce ANCA and autoimmunity when injected into naive mice.

155 CAs), but most patients with neuropathy lack ANCAs.

156 , microscopic polyangiitis, or renal-limited ANCA-associated vasculitis in complete remission after a

157 copic polyangiitis, and 5 with renal-limited ANCA-associated vasculitis) received azathioprine (58 pa

158 eping the inflammasome in check and limiting ANCA-induced inflammation.

159 In conclusion, longitudinal ANCA measurements may be useful in patients with renal i

160 The value of measuring ANCA during follow-up to predict a relapse is controvers

161 logic insights, we postulated that measuring ANCA is useful in patients with renal involvement but is

162 icity, such as PR3 ANCA-positive MPA and MPO ANCA-positive MPA, provide a more useful tool than the c

163 CA with specificity for myeloperoxidase (MPO ANCA) versus ANCA with specificity for proteinase 3 (PR3

164 twice as likely to relapse as those with MPO ANCA (HR 1.89 [95% CI 1.33-2.69], P = 0.0004), and ANCA

165 einase 3 (PR3)-ANCA or myeloperoxidase (MPO)-ANCA, were included in our study, followed at regular in

166 ions for patients with myeloperoxidase (MPO)-ANCA-associated GN are needed.

167 Myeloperoxidase (MPO)-ANCA-associated GN is a significant cause of renal failu

168 in experimental murine myeloperoxidase (MPO)-ANCA-associated vasculitis (AAV) show mast cells degranu

169 MPO+ ANCA EGPA is an eosinophilic autoimmune disease sharing

170 features and an HLA-DQ association with MPO+ ANCA-associated vasculitis, while ANCA-negative EGPA may

171 induces anti-MPO T-cell autoimmunity and MPO-ANCA in mice, whereas related sequences do not.

172 r intervals, and tested for PR3-ANCA and MPO-ANCA.

173 of myeloperoxidase-specific antibodies (MPO-ANCA).

174 The role of genetics in MPO-ANCA NCGN severity was investigated using 13 inbred mous

175 effector responses can induce injury in MPO-ANCA-associated microscopic polyangiitis.

176 teinase 3 (PR3-ANCA) or myeloperoxidase (MPO-ANCA).

177 as induced either by passive transfer of MPO-ANCA and LPS or by planting MPO(409-428) conjugated to a

178 this methodology led to the discovery of MPO-ANCA in ANCA-negative disease that reacted against a sol

179 There is evidence that MPO-ANCA cause necrotizing and crescentic glomerulonephritis

180 l involvement (72 with PR3-ANCA, 32 with MPO-ANCA) and 62 patients had nonrenal disease (36 with PR3-

181 renal disease (36 with PR3-ANCA, 26 with MPO-ANCA).

182 deficient bone marrow developed worsened MPO-ANCA-induced NCGN.

183 CA-associated vasculitis and myeloperoxidase ANCA-associated vasculitis are distinct autoimmune syndr

184 Anti-myeloperoxidase ANCA was associated with HLA-DQ (P=2.1x10(-8)).

185 eutrophil myeloperoxidase in myeloperoxidase-ANCA-associated microscopic poliangiitis providing a pot

186 s similar in both those with myeloperoxidase-ANCA and proteinase 3-ANCA.

187 anti-LAMP-2 reactivity was present in 21% of ANCA sera from two of the centers; reactivity was presen

188 and, for EGPA, by the presence or absence of ANCA (ANCA(+) or ANCA(-), respectively).

189 eroxidase (MPO) underlies the development of ANCA-associated vasculitis and GN, but the mechanisms un

190 Therefore, we studied the effect of ANCA on NF-kappaB activation in neutrophil/EC cocultures

191 The two salient features of ANCA-associated vasculitis (AAV) are the restricted micr

192 We report a novel finding of ANCA reactivity in the sputa of patients with eGPA in wh

193 hil cytoplasmic antibodies are a hallmark of ANCA-associated vasculitides and are likely to be integr

194 elapse-free period (P<0.001), independent of ANCA serotype.

195 Bony erosion was independent of ANCA status or systemic involvement.

196 ents with biopsy-proven renal involvement of ANCA-associated vasculitis.

197 ouse MPO (anti-MPO) induces a mouse model of ANCA NCGN that closely mimics human disease.

198 ate the underlying cause and pathogenesis of ANCA vasculitis.

199 ANCAs) may contribute to the pathogenesis of ANCA-associated vasculitis are not well understood.

200 This study confirms that the pathogenesis of ANCA-associated vasculitis has a genetic component, show

201 rophil microparticles in the pathogenesis of ANCA-associated vasculitis, potentially providing a targ

202 ctivation is involved in the pathogenesis of ANCA-associated vasculitis.

203 immunodominant epitopes in the pathology of ANCA-associated vasculitis and suggest that autoantibody

204 tions were with the antigenic specificity of ANCA, not with the clinical syndrome.

205 myeloid dendritic cells and the induction of ANCAs and associated autoimmunity.

206 results in the induction and persistence of ANCAs is not well understood.

207 We also tested the effect of AZM198 on ANCA-stimulated neutrophil-mediated endothelial cell dam

208 GPA and MPA; and 3) classification based on ANCA with specificity for myeloperoxidase (MPO ANCA) ver

209 the presence or absence of ANCA (ANCA(+) or ANCA(-), respectively).

210 of inflammatory bowel disease had elevated p-ANCA antibody levels compared to 3 of 15 controls (20%)

211 g bowel disease, and one-half had elevated p-ANCA levels.

212 ear antineutrophil cytoplasmic antibodies (p-ANCAs) with specificities for 'atypical' antigens.

213 In this study, both polyclonal ANCAs isolated from patients and chimeric proteinase 3-A

214 Finally, IgG from LAMP-2-positive ANCA-negative patients bound specifically to normal huma

215 ADAM17 in active proteinase-3 (PR3)-positive ANCA-associated vasculitis (AAV).

216 re were 38 (40.9%) of 93 cases with positive ANCA results, of which 15 cases reported a positive ELIS

217 ANCA with specificity for proteinase 3 (PR3 ANCA).

218 ualized based on serial B lymphocyte and PR3 ANCA monitoring.

219 at incorporate ANCA specificity, such as PR3 ANCA-positive MPA and MPO ANCA-positive MPA, provide a m

220 cificity was predictive of relapse, with PR3 ANCA-positive patients almost twice as likely to relapse

221 Concomitant injection of anti-PR3 ANCAs with PR3-expressing apoptotic cells induced a Th17

222 itis, positive for either proteinase 3 (PR3)-ANCA or myeloperoxidase (MPO)-ANCA, were included in our

223 trophil proteins leukocyte proteinase 3 (PR3-ANCA) or myeloperoxidase (MPO-ANCA).

224 sociation between the DRB1*15 allele and PR3-ANCA disease, among African Americans.

225 The differences between PR3-ANCA-associated vasculitis (AAV) and MPO-AAV described i

226 teinase-3 (PR3) mAb and serum containing PR3-ANCA from patients with active vasculitis both induced a

227 wed at regular intervals, and tested for PR3-ANCA and MPO-ANCA.

228 lleles contribute to the pathogenesis of PR3-ANCA disease.

229 A retrospective cohort study of MPO- or PR3-ANCA-positive patients with AAV (MPA and GPA) and severe

230 However, the serum containing polyclonal PR3-ANCA did not induce release of sFlt1 from cultured human

231 2 patients had nonrenal disease (36 with PR3-ANCA, 26 with MPO-ANCA).

232 patients had renal involvement (72 with PR3-ANCA, 32 with MPO-ANCA) and 62 patients had nonrenal dis

233 ence of cocaine in any patient with presumed ANCA vasculitis, and if positive, then urine should also

234 r necrosis and crescent formation in a renal ANCA-associated vasculitis model.

235 s were higher in sera of patients with renal ANCA disease compared with those in sera of patients wit

236 n a prospective study of patients with renal ANCA disease.

237 uspicion should be maintained, with repeated ANCA testing, biopsy, and imaging where indicated, espec

238 it is a single disease entity and what role ANCA plays in its pathogenesis.

239 ed from 23 patients with eGPA (n = 10, serum ANCA(+)), 19 patients with eosinophilic asthma (predniso

240 nical relevance of sputum ANCAs in the serum ANCA(-) patients with eGPA.

241 ls (P < 0.0001), irrespective of their serum ANCA status.

242 rine (AZA) for remission-induction in severe ANCA-associated vasculitis (AAV), but renal outcomes are

243 In patients with severe ANCA-associated vasculitis, a single course of rituximab

244 Pathogenicity of detected sputum ANCA was assessed using in vitro degranulation assays.

245 In addition, 16 of 17 (94%) of sputum ANCA(+) patients had clinical manifestations of severe a

246 hma compared with 3 of 6 (50%) in the sputum ANCA(-) subset (P = 0.04).

247 , 74%) showed significantly increased sputum ANCAs compared with patients with eosinophilic asthma (P

248 he presence and clinical relevance of sputum ANCAs in the serum ANCA(-) patients with eGPA.

249 Still, ANCA pathogenesis remains obscure.

250 ovide insight into how PR3 and PR3-targeting ANCAs promote GPA pathophysiology.

251 Here we report that ANCA induces neutrophil extracellular traps (NETs) via r

252 We suggest that ANCA-stimulated neutrophils activate endothelial NF-kapp

253 The ANCA-associated GN (AGN) classification categorizes pati

254 The ANCA-associated vasculitides, granulomatosis with polyan

255 s failed to reveal a specific target for the ANCA IgG.

256 xpressed a variety of markers, including the ANCA autoantigens proteinase 3 and myeloperoxidase.

257 The genesis of the ANCA autoimmune response is a multifactorial process tha

258 el localization of the disease is due to the ANCA antigen accessibility, which is restricted to the m

259 ivation of these cells by ANCA is central to ANCA-associated vasculitis and necrotizing crescentic gl

260 rance to neutrophil proteins, which leads to ANCA-mediated neutrophil activation, recruitment and inj

261 re, we detected LAMP-2 autoantibodies in two ANCA-negative patients.

262 In patients with GN or vasculitis, ANCAs are directed against proteinase 3 (PR3) or myelope

263 ficity for myeloperoxidase (MPO ANCA) versus ANCA with specificity for proteinase 3 (PR3 ANCA).

264 ivation in neutrophil/EC cocultures in vitro ANCA did not activate NF-kappaB in primed human neutroph

265 d be closely considered in any patient where ANCA vasculitis is entertained given the wide use of the

266 is a highly inflammatory condition in which ANCA-activated neutrophils interact with the endothelium

267 with MPO+ ANCA-associated vasculitis, while ANCA-negative EGPA may instead have a mucosal/barrier dy

268 n exist in disease-free individuals, and why ANCA are undetected in patients with ANCA-negative disea

269 scopic polyangiitis that are associated with ANCA specificity, and suggests that the response against

270 ly discuss all drug culprits associated with ANCA vasculitis and then focus on clinical, serologic, t

271 r immunoglobulin deposits is associated with ANCA.

272 -complex (MHC) and non-MHC associations with ANCA-associated vasculitis and also that granulomatosis

273 icroparticles in the plasma of children with ANCA-associated vasculitis compared with that in healthy

274 NCGN severity varies among patients with ANCA disease, and genetic factors influence disease seve

275 ry low titers in a minority of patients with ANCA disease.

276 es (two academic centers) from patients with ANCA glomerulonephritis (n=329); those with ANCA-negativ

277 upregulated in the kidneys of patients with ANCA-associated crescentic GN and a murine model of cres

278 are enriched in the kidneys of patients with ANCA-associated crescentic GN and colocalize with CXCR3(

279 upregulated in the kidneys of patients with ANCA-associated crescentic GN as opposed to patients wit

280 s of renal biopsy samples from patients with ANCA-associated crescentic GN.

281 More patients with ANCA-associated vasculitides had sustained remission at

282 Treatment of patients with ANCA-associated vasculitis (AAV) and severe renal involv

283 ral to disease pathogenesis in patients with ANCA-associated vasculitis (AAV).

284 discovery cohort of 1233 U.K. patients with ANCA-associated vasculitis and 5884 controls and was rep

285 eloperoxidase concentration in patients with ANCA-associated vasculitis and controls, and assessed ne

286 ht have therapeutic benefit in patients with ANCA-associated vasculitis and GN.

287 We measured NGAL in patients with ANCA-associated vasculitis and mice with anti-myeloperox

288 tudinal analysis revealed that patients with ANCA-associated vasculitis could be divided into two gro

289 ctively, among three groups of patients with ANCA-associated vasculitis from Vienna, Austria (n=19);

290 ase 3 (PRTN3) in leukocytes of patients with ANCA-associated vasculitis observed longitudinally (n=82

291 Observations in patients with ANCA-associated vasculitis suggest that CD8(+) T cells p

292 cheme with which to categorize patients with ANCA-associated vasculitis, but adding the percentage of

293 hundred sixty-six consecutive patients with ANCA-associated vasculitis, positive for either proteina

294 n be detected in most European patients with ANCA-associated vasculitis.

295 ted endothelial cell damage in patients with ANCA-associated vasculitis.

296 and why ANCA are undetected in patients with ANCA-negative disease.

297 In conclusion, in patients with ANCA-negative piFNGN, we have identified autoantibodies

298 ANCA glomerulonephritis (n=329); those with ANCA-negative glomerulonephritis (n=104); those with fim

299 utoantigens in patients with vasculitis with ANCA.

300 izing GN (piFNGN) is usually associated with ANCAs that are thought to be pathogenic.